2021 looks set to be a big year for cannabis reform in the US now that the new White House administration has signalled that cannabis reform is one of its top priorities, and the US public supports cannabis reform in unprecedented numbers.
Keep up to date with the latest changes in federal regulation impacting the US market for CBD market with news, data and research at the CBD-Intel hub.
Last year saw no movement on cannabinoid issues at federal level in the US, as CBD-Intel predicted, and it’s not looking too good for this year either – though we anticipate some continued movement at state level
After early promise, no cannabis-focused legislation has yet made it onto president Joe Biden’s desk for signing. So why is that?
US representatives have introduced a bill into the House aiming to push the US Food and Drug Administration (FDA) to regulate CBD in food and drinks
“Intoxicating” will be the word to watch for and THC will be the main driver for developments in 2022, CBD-Intel predicts
CBD-Intel was on point in its 2021 predictions. Much like the preceding year, we believed 2021 would largely be defined more by what did not happen than what did
If 2020 was the year in the waiting-room then 2021 was perhaps the year of the unfulfilled hype. As predicted, there was little movement in many of the major issues controlling the CBD market
Does the United States Postal Service (USPS) really have the authority to permit the shipping of CBD vaping products under the PACT Act?
Some sellers of intoxicating cannabinoid products claim legality under the 2018 US Farm Bill. CBD-Intel believes that many hemp-derived cannabinoids do not violate federal controlled substance law
Nancy Mace, a first-term Republican Congresswoman from South Carolina, recently introduced a bill in the House of Representatives that would decriminalise cannabis at the federal level
Rahul Gupta has been confirmed by the US Senate as director of National Drug Control Policy, while president Joe Biden intends to nominate Robert Califf as head of the US Food and Drug Administration (FDA)
It owns one of North America’s biggest chains of convenience stores and fuel stations – now Alimentation Couche-Tard may have the potential to become one of its foremost providers of cannabis and CBD
It turns out the Charlotte’s Web application to the US FDA for the registration of a full spectrum hemp extract as a new dietary ingredient (NDI) DID include data from the ValidCare industry study
The lack of a clear regulatory pathway to market for CBD products in the US is highlighted by a row over the FDA’s denial of new dietary ingredient (NDI) approval for full spectrum hemp extracts
Does the CBD industry now face increased scrutiny from the US Securities and Exchange Commission (SEC)?
A lack of regulatory clarity is the primary reason behind a predicted dramatic fall in hemp acreage dedicated to the production of CBD in the US
Enforcement action against companies pushing the limits on marketing delta-8 THC products in the US is likely following a health advisory from the FDA and CDC
The US Food and Drug Administration (FDA) and Centers for Disease Control (CDC) have issued warnings about the rise of reported incidents in the US regarding the use of delta-8 THC
CBD products are not eligible for trademark protection, US regulators have reaffirmed, because they are not legal under the federal Food, Drug, and Cosmetic Act (FDCA)
What is delta-8 THC and how does US law deal with it, at both federal and state level? In this presentation, CBD-Intel legal analyst Anthony Traurig shares his insights
CBD pet products remain in a grey area in terms of both legality and effectiveness – but there have been some attempts in both to shed light into the darkness
The FDA recently rejected applications from both Charlotte’s Web and Irwin Naturals to use a hemp extract as a dietary supplement
There remains no certainty over the future regulation of ingestible CBD products in many jurisdictions
The US Postal Service (USPS) is still shipping CBD vape products for now – but the latest version of the Prevent All Cigarette Trafficking (PACT) Act leaves a lot of uncertainty over the exact legal position
A CBD company’s punishment by the US Federal Trade Commission (FTC) for making false or misleading health claims has been confirmed
Licensing issues look set to become the next big US lobbying battleground for cannabis as money moves on from the traditional legalisation-versus-prohibition field
Lina Khan’s appointment to chair the US Federal Trade Commission (FTC) – confirmed last month – was a bit of a surprise
As CBD grows in popularity, its regulatory status remains poorly defined. In this report CBD-Intel reviews the regulatory framework of dietary supplements and where CBD fits, or would fit, within that framework
Delta-8 THC has emerged as the hottest new cannabinoid in the US market. This report examines federal law on delta-8, notes trends that are happening at state level, and discusses what the future may hold
A CBD company has been fined more than $30,000 by the US Federal Trade Commission (FTC) in the first such punishment since a crackdown on false or misleading health claims was announced in December
Tim Phillips, CBD-Intel’s managing director, recently presented at CBD Live during VOXPO – Virtual Online Vape & CBD Expo on 28th April 2021. In addition to an overview of the impact of Covid-19 on the retail environment, he provided a comparative analysis of the current Novel Food legislation in the UK and the US, as […]
Significant cannabis reform is inevitably coming to congress, no matter whether the Biden administration considers it a priority, and giants in experienced lobbying industries are preparing their agents
A new deputy commissioner at the US Food and Drug Administration (FDA) will likely be the single person with the most influence on the path to market for CBD in the US
Access to banking services has been a problem for the legal cannabis sector in the US from the beginning – and the experience of one cooperative in Michigan shows that the relationship can be problematic for financial institutions too
The US Customs and Border Protection (CBP) agency is wrongly seizing legal hemp and hemp-related shipments – such as farm equipment that it claims constitutes drug paraphernalia – according to two recently-filed lawsuits
CBD companies see more synergies than threats from the provision of legal cannabis products in states such as Colorado, which has one of the oldest recreational cannabis markets in the US
The US Food and Drug Administration (FDA) has assessed a combined health claim for the first time and denounced the practice of promoting CBD on a product making qualified health claims based on other ingredients
The US Food and Drug Administration (FDA) has told two CBD companies they fell short of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and ordered them to undertake proper testing
Podcasts editor Jon Bruford is joined by Anthony Traurig, CBD-Intel legal analyst and US specialist, to discuss the legal and regulatory concerns that hang over cannabis in the US and Canada and the economic impact of Covid-19
CBD-Intel podcasts editor Jon Bruford is joined by the founder and principal of Kight Law Office, Rod Kight, a specialist in cannabis business law in the US
The heir to the Wrigley’s chewing gum fortune, Beau Wrigley, has entered into a deal he claims will accelerate the growth of his multi-state cannabis company, Parallel, and change the landscape of the US cannabis market
Marlboro cigarette manufacturer Altria has stated its support for the federal legalisation of cannabis – with a view to Cronos, the Canadian cannabis company in which it has a major stake, thriving in a legal US market
A US association of cannabis regulators has written to Congress urging the modernisation of cannabis policy at federal level
The US Federal Trade Commission (FTC) could take a more discerning approach to enforcement against CBD companies under the new administration in Washington
The Democratic Party, which now controls Congress and the presidency, has signalled for some time that cannabis reform is one of its top priorities, and the US public supports that reform in unprecedented numbers
US president Joe Biden’s appointees to a number of influential positions in the new administration give reason for optimism within the hemp and cannabis sector
The US Small Business Administration (SBA) has highlighted its role in securing changes to the Department of Agriculture (USDA)’s final rule for hemp production
CBD-Intel presents some predictions of what regulatory moves could take place around cannabis, hemp and CBD in the US in 2021
President elect Joe Biden still looks to be somewhat reluctant to too closely embrace cannabis reform as an issue. But effective control of the senate through victories by Raphael Warnock and Jon Ossoff in special run-off elections in the state of Georgia give Democrats 48 seats with two independents that generally vote democratic (and would […]
Reform of cannabis laws at federal level in the US looks to be a step closer following the likely victory of the Democratic party in run-off elections for both Senate seats in the state of Georgia
For many 2020 will always carry an asterisk. The CBD industry was – overall – more fortunate than many other sectors
In December 2018 the Farm Bill removed hemp – defined as cannabis – and its derivatives, from the definition of marijuana in the Controlled Substances Act.
This paved the way for the legal cultivation, sale and distribution of the hemp plant but also led to led to the misperception that all products made from or containing hemp, including those made with CBD, were now legal to sell in interstate commerce.
Two years on, there is still a lack of clarity around what is and isn’t legal and the CBD industry is held back by lack of federal regulation and a patchwork of consumer and products safety standards and guidance.
Industry stakeholders have called for more joined up regulation, including increased protection of state legalisation frameworks, access to banking for cannabis firms, harmonised standards for consumer and product safety and lab testing, and relaxation of federal constraints on research.
With frustrations mounting over the Food and Drug Administration’s (FDA’s) slow pace, Congress could take matters into its own hands by passing legislation to move the industry forward.
Though Biden himself seemingly remains sceptical about recreational cannabis – having previously stated it should be placed in Schedule II under the Controlled Substances Act category – many of his major appointments appear to be solid supporters of hemp and cannabis, which gives the industry reason for optimism.
Stay on top of the ever-changing regulatory landscape with our CBD-Intel hub, which provides access to our news briefings, data and reports on developments related to US federal regulation.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
